WEEK 12 CLINICAL RESPONSE TO CERTOLIZUMAB PEGOL PREDICTS LONG-TERM OUTCOMES REGARDLESS OF CONCOMITANT MEDICATIONS AND BASELINE DISEASE CHARACTERISTICS IN JAPANESE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
WEEK 12 CLINICAL RESPONSE TO CERTOLIZUMAB PEGOL PREDICTS LONG-TERM OUTCOMES REGARDLESS OF CONCOMITANT MEDICATIONS AND BASELINE DISEASE CHARACTERISTICS IN JAPANESE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
复制标题
第 12 周，CERTOLIZUMAB PEGOL 的临床反应可预测日本活动性类风湿性关节炎患者的长期结果，无论是否同时服用药物和基线疾病特征
DOI：
--
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
N. Miyasaka.
中科院分区：
文献类型：
--
作者：
H. Yamanaka;K. Yamamoto;T. Takeuchi;N. Ishiguro;Y. Tanaka;K. Eguchi;A. Watanabe;H. Origasa;T. Shoji;S. Onodera;N. Miyasaka.
